The loss of benefit from intrathecal baclofen, with increased spastIcIty and a discrepancy between the residual and the calculated volume content (underinfu sion), made us suspect dysfunction of the intrathecal baclofen infusion in a paraplegic patient. Although all possible usual checking methods were used, no failure in the drug administration device (DAD) could be found. Despite some benefit from increasing the daily dose of baclofen, it has not been possible to control the spastic symptoms. Surgery was therefore decided upon, and a small leak at the end of the catheter tip was discovered. Surgeons and physicians should be aware that checking methods of DAD cannot exclude failure of the system. Their errors and limitations are discussed.
Introduction
Intrathecal drug administration devices In cases of suspected pump failures, physicians should, after having eliminated any other possible cause of the increased spasticity, completely check the DAD ac cording to an established protocol. 8 We report a patient with suspected DAD dysfunction, where the diagnosis of failure could not be made according to this proto col, thus making surgery inevitable.
Case report
A 24 year old man was involved in an accident in April 1987 with a consequent fracture-dis location T8 and complete spastic paraplegia below T8.
In April 1991, due to intractable spasm, implantation of the drug administration device (DAD) was performed. A 4F 'Silastic catheter' «Model 8703) Metronic Inc, Minneapolis USA) was introduced through a Tuohy needle, under general anaesthesia between L3 and L4 and the tip pushed rostrally 10-15 cm into the subarach noid space, reaching, at least, the Tll-Ll level. The catheter position was confirmed intraoperatively by fluoroscopy and post operatively by radiography. The catheter was sutured to the fascia and tunnelled subcuta neously to the left abdominal wall, where a pocket for the DAD was made. The DAD was also sutured to the fascia and was connected to the catheter. The implantable pump (Syn chromed, Model 8611H, Metronic Inc, Minnea polis USA) was filled with 18 ml of the drug in a concentration of 500 fLg/ml (delivered by Ciba Geigy Corp, Basel, Switzerland). The flow was started shortly after implantation, in a continu ous infusion mode. Drug delivery was pro grammed through a physician'S microcomputer and transmitted to the implanted pump non invasively via a hand held radiofrequency tele metry wand. A daily dose of 60 fLg was found to be adequate to control the spasticity. Refills were performed by a percutaneous puncture through a rubber septum in the pump device with intervals of 90 days.
In December 1991 the patient presented be cause of recent increase of spasms. No particu larity returned to the anamnesis. Neurostatus testing of rigidity and spasms showed an Ash worth scale score of 5 and 5, respectively. No causes of increased nociceptive response could be found and general laboratory tests remained without any specificity. Checking of the pump function showed a discrepancy between residual volume content and calculated volume content (underinfusion). Further investigations revealed no reason for DAD dysfunction. Neither cath eter disconnection, kink or dislodgement were seen in the plain xray (Fig 1) . Control of the pump-rotor movement, by programming a bolus calculated as described to produce a rotor movement of 90° in 45 s.
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implied an adequate pump function (Fig 2) .
Filling up the pump with 10 ml of a radio opaque solution (Iopamiro) did not provide any useful information. This solution could not be detected, either at the catheter tip, or at a possible site of catheter dysfunction, even after three boluses of 0.5 ml (Fig 3) . 2 Filling up the pump with 5-10 ml of a 
